Ana F. Costa

Ana F. Costa

Auto-generated profile, based on publicly available information

Ana F. Costa

Department of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in MRS Bulletin
Verified
Journal Article
Closed access
PDF file
EREleftheria Roumeli
Eleftheria Roumeli
SASourena Azidhak
Sourena Azidhak
ACAna F. Costa
Ana F. Costa
ACAnlan Chen
Anlan Chen
ISIo Saito
Io Saito
KSKayla Sprenger
Kayla Sprenger

2 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDavid Saeb
David Saeb
ELEmma E. Lietzke
Emma E. Lietzke
EWEvan A. Wood
Evan A. Wood
ACAna F. Costa
Ana F. Costa
EAEmma C. Aldrich
Emma C. Aldrich
KSKayla G. Sprenger
Kayla G. Sprenger
Triggering receptor expressed on myeloid cells 2 (TREM2) is a regulator of microglial function in Alzheimer’s disease (AD), and its soluble ectodomain (sTREM2) has emerged as a potential neuroprotective factor. Recent work shows that sTREM2 exerts protective effects through direct interaction with neuronal transgelin-2 (TG2) and modulates downstream tau pathology, yet the molecular basis of this interaction remains unknown. Here, we use all-atom molecular dynamics simulations to define the structural mechanisms of sTREM2–TG2 binding. We identify an electrostatically driven interface centered on the TG2 calponin homology domain. This surface is engaged by a binding motif on sTREM2 in which charged anchoring residues are flanked by hydrophobic contacts. We further show that the AD-risk TREM2 R47H variant maintains a more open, solvent-exposed CDR2 loop that redistributes interfacial contacts while preserving overall binding affinity, offering a structural explanation for reports that R47H does not exacerbate tau pathology in tauopathy models. Leveraging these insights, we design optimized sTREM2-derived peptides that outperform a previously reported therapeutic peptide in binding persistence, energetics, and recapitulation of native TG2 contacts, supporting engagement at the epitope through which sTREM2 suppresses tau phosphorylation. Taken together, our results define a mechanistic framework for the sTREM2–TG2 axis in AD and establish a structure-guided strategy for developing peptide modulators of this interaction.